These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 22967802

  • 1. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
    Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, Meyn R.
    Radiat Oncol; 2012 Sep 11; 7():154. PubMed ID: 22967802
    [Abstract] [Full Text] [Related]

  • 2. The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.
    Jing C, Ning J, Yuanjie N.
    J Cancer Res Clin Oncol; 2012 Dec 11; 138(12):2137-43. PubMed ID: 22868821
    [Abstract] [Full Text] [Related]

  • 3. Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells.
    Diaz R, Nguewa PA, Redrado M, Manrique I, Calvo A.
    Prostate; 2015 Aug 01; 75(11):1137-49. PubMed ID: 25893276
    [Abstract] [Full Text] [Related]

  • 4. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM.
    Mol Cancer Ther; 2003 May 01; 2(5):471-8. PubMed ID: 12748309
    [Abstract] [Full Text] [Related]

  • 5. Sunitinib mesylate inhibits proliferation of human colonic stromal fibroblasts in vitro and in vivo.
    Wang ZH, Li Q, Ruan SQ, Xiao Q, Liu Y, Hu YT, Hu LF, Chen HY, Zheng S, Zhang SZ, Ding KF.
    J Zhejiang Univ Sci B; 2014 Aug 01; 15(8):701-12. PubMed ID: 25091988
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
    Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.
    Mol Cancer Ther; 2006 Jul 01; 5(7):1774-82. PubMed ID: 16891463
    [Abstract] [Full Text] [Related]

  • 8. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.
    Cancer Res; 2010 Feb 01; 70(3):1053-62. PubMed ID: 20103629
    [Abstract] [Full Text] [Related]

  • 9. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
    Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST.
    Mol Cancer Ther; 2011 May 01; 10(5):861-73. PubMed ID: 21441409
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 12. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D, Tang F, Wang S, Jiang Z, Zhang L.
    Cancer Chemother Pharmacol; 2012 Jan 01; 69(1):173-83. PubMed ID: 21638122
    [Abstract] [Full Text] [Related]

  • 13. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M.
    Int J Cancer; 2010 Sep 01; 127(5):1197-208. PubMed ID: 20039326
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
    Cao C, Albert JM, Geng L, Ivy PS, Sandler A, Johnson DH, Lu B.
    Cancer Res; 2006 Dec 01; 66(23):11409-15. PubMed ID: 17145887
    [Abstract] [Full Text] [Related]

  • 16. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A, Brossa A, Bernardini M, Genova T, Grolez G, Villers A, Leroy X, Prevarskaya N, Gkika D, Bussolati B.
    BMC Cancer; 2014 Dec 12; 14():939. PubMed ID: 25494980
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
    Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV.
    Oncogene; 2010 May 20; 29(20):2938-49. PubMed ID: 20208561
    [Abstract] [Full Text] [Related]

  • 19. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
    Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, Camphausen K, Citrin D.
    Clin Cancer Res; 2009 May 01; 15(9):3050-7. PubMed ID: 19366835
    [Abstract] [Full Text] [Related]

  • 20. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
    Zhang J, Zhou J, Ren X, Diao Y, Li H, Jiang H, Ding K, Pei D.
    Invest New Drugs; 2012 Apr 01; 30(2):490-507. PubMed ID: 21080210
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.